Blood Advances

Journal

Publication Venue For

  • B-cell acute lymphoblastic leukemia in patients with germline RUNX1 mutations.  5:3199-3202. 2021
  • Phase 3 randomized trial of chemotherapy with or without oblimersen in older AML patients: CALGB 10201 (Alliance).  5:2775-2787. 2021
  • Gene expression signature predicts relapse in adult patients with cytogenetically normal acute myeloid leukemia.  5:1474-1482. 2021
  • Daratumumab plus RVd for newly diagnosed multiple myeloma: Final analysis of the safety run-in cohort of GRIFFIN.  5:1092-1096. 2021
  • Comparison of CALGB 10403 (Alliance) and COG AALL0232 toxicity results in young adults with acute lymphoblastic leukemia.  5:504-512. 2021
  • Acute erythroid leukemia is enriched in NUP98 fusions: A report from the Children's Oncology Group.  4:6000-6008. 2020
  • Elevated plasma levels of syndecan-1 and soluble thrombomodulin predict adverse outcomes in thrombotic thrombocytopenic purpura.  4:5378-5388. 2020
  • Systems-based hematology: Highlighting successes and next steps.  4:4574-4583. 2020
  • American society of hematology 2020 guidelines for treating newly diagnosed acute myeloid leukemia in older adults.  4:3528-3549. 2020
  • Myelodysplastic syndrome unrelated to lentiviral vector in a patient treated with gene therapy for sickle cell disease.  4:2058-2063. 2020
  • A phase 2 study of ATRA, arsenic trioxide, and gemtuzumab ozogamicin in patients with high-risk APL (SWOG 0535).  4:1683-1689. 2020
  • Patterns of care and clinical outcomes with cytarabine-anthracycline induction chemotherapy for AML patients in the United States.  4:1615-1623. 2020
  • Thrombotic, inflammatory, and HIF-regulated genes and thrombosis risk in polycythemia vera and essential thrombocythemia.  4:1115-1130. 2020
  • Clinical and functional significance of circular RNAs in cytogenetically normal AML.  4:239-251. 2020
  • Outcomes of patients with limited-stage aggressive large B-cell lymphoma with high-risk cytogenetics.  4:253-262. 2020
  • Sex differences in the trajectory of glomerular filtration rate in pediatric and murine sickle cell anemia.  4:263-265. 2020
  • Longitudinal assessments of plasma ADAMTS13 biomarkers predict recurrence of immune thrombotic thrombocytopenic purpura.  3:4177-4186. 2019
  • American Society of Hematology 2019 guidelines for sickle cell disease: Cardiopulmonary and kidney disease.  3:3867-3897. 2019
  • End points for sickle cell disease clinical trials: Renal and cardiopulmonary, cure, and low-resource settings.  3:4002-4020. 2019
  • Hyperfiltration predicts long-term renal outcomes in humanized sickle cell mice.  3:1460-1475. 2019
  • Phase 1b study of the MDM2 inhibitor AMG 232 with or without trametinib in relapsed/refractory acute myeloid leukemia.  3:1939-1949. 2019
  • Defining the epigenetic status of blood cells using a cyanine-based fluorescent probe for PRMT1.  2:2829-2836. 2018
  • The impact of phlebotomy and hydroxyurea on survival and risk of thrombosis among older patients with polycythemia vera.  2:2681-2690. 2018
  • Platelet transfusions improve hemostasis and survival in a substudy of the prospective, randomized PROPPR trial.  2:1696-1704. 2018
  • Ten-year outcome of patients with acute myeloid leukemia not treated with allogeneic transplantation in first complete remission.  2:1645-1650. 2018
  • T-cell prolymphocytic leukemia in an adolescent with ataxiatelangiectasia: Novel approach with a JAK3 inhibitor (tofacitinib).  1:2724-2728. 2017
  • Allogeneic bone marrow transplant in the absence of cytoreductive conditioning rescues mice with β-thalassemia major.  1:2421-2432. 2017
  • Mesenchymal stem cells expressing osteoprotegerin variants inhibit osteolysis in a murine model of multiple myeloma.  1:2375-2385. 2017
  • Recent trends in multiple myeloma incidence and survival by age, race, and ethnicity in the United States.  1:282-287. 2017
  • Therapeutic efficacy of the platelet glycoprotein Ib antagonist anfibatide in murine models of thrombotic thrombocytopenic purpura..  1:75-83. 2016

    • International Standard Serial Number (issn)

  • 2473-9529

    • Electronic International Standard Serial Number (eissn)

  • 2473-9537